Zingerone Nanotetramer Strengthened the Polypharmacological Efficacy of Zingerone on Human Hepatoma Cell Lines
Source abstract
Abstract
We base this study on the concept of drug repositioning to reconstitute the natural product of zingerone as zingerone nanoparticles (zingerone NPs) through a one-pot synthesized process. The as-fabricated zingerone NPs were characterized; they possessed a particle size of 1.42 ± 0.67 nm and a reconstituted structure of zingerone nanotetramer. We further validate the effects of zingerone NPs on the antitumor activity and investigate the relative underlying mechanisms on the human hepatoma SK-Hep-1 and Huh7 cell lines. Our results demonstrated that zingerone NPs significantly inhibit Akt activity and NFκB expression as well as activate the caspases cascade signaling pathway which are involved in the antiproliferation, antitumorigenicity, disturbing cell cycle progression, and induction of DNA damage as well as cell apoptosis. These findings were promising to provide a "Nano-chemoprevention" strategy in future cancer therapeutics and medical and clinical applications.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Ginger and Zingiberaceae research · Curcumin's Biomedical Applications · Piperaceae Chemical and Biological Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Doctoral Degree Program in Marine Biotechnology, Academia Sinica, Taipei 11529, Taiwan
Department of Seafood Science, National Kaohsiung University of Science and Technology, Kaohsiung 81157, Taiwan
Department of Food and Nutrition, Providence University, Taichung 43301, Taiwan
Funding
Ministry of Science and Technology, Taiwan
References (56)
Show source-provided references
1. 10.1016/j.addr.2016.04.02510.1016/j.addr.2016.04.025 ↗
2. 10.1016/j.addr.2013.09.01910.1016/j.addr.2013.09.019 ↗
3. 10.1002/jsfa.259810.1002/jsfa.2598 ↗
4. 10.1208/aapsj08022810.1208/aapsj080228 ↗
5. Sporn M. B. · Cancer Res. · 1976 · 36 · 2699
6. 10.3322/canjclin.54.3.15010.3322/canjclin.54.3.150 ↗
7. 10.2147/ijn.s9216210.2147/ijn.s92162 ↗
8. 10.2174/13894500677605491510.2174/138945006776054915 ↗
9. 10.21101/cejph.a388610.21101/cejph.a3886 ↗
10. 10.1155/2013/16275010.1155/2013/162750 ↗
11. 10.1002/anie.20110772410.1002/anie.201107724 ↗
12. 10.2174/138161281131911000410.2174/1381612811319110004 ↗
13. 10.1016/j.fct.2006.11.00210.1016/j.fct.2006.11.002 ↗
14. 10.1016/j.arabjc.2017.05.01110.1016/j.arabjc.2017.05.011 ↗
15. 10.1186/1749-8546-6-2710.1186/1749-8546-6-27 ↗
16. 10.1016/j.soncn.2005.04.00610.1016/j.soncn.2005.04.006 ↗
17. 10.1016/j.phrs.2009.01.01710.1016/j.phrs.2009.01.017 ↗
18. 10.1016/j.drudis.2010.02.00910.1016/j.drudis.2010.02.009 ↗
19. 10.1039/c4cs00269e10.1039/c4cs00269e ↗
20. 10.1080/21691401.2017.139534410.1080/21691401.2017.1395344 ↗
21. 10.1016/s1872-2040(16)60990-810.1016/s1872-2040(16)60990-8 ↗
22. 10.1038/srep0170310.1038/srep01703 ↗
23. 10.1007/s12274-014-0479-y10.1007/s12274-014-0479-y ↗
24. 10.1021/sc500242k10.1021/sc500242k ↗
25. 10.1016/j.jbiotec.2014.08.04310.1016/j.jbiotec.2014.08.043 ↗
26. 10.1155/2015/81636410.1155/2015/816364 ↗
27. 10.1021/nn300760g10.1021/nn300760g ↗
28. 10.1016/j.cell.2011.02.01310.1016/j.cell.2011.02.013 ↗
29. 10.7453/gahmj.2013.00910.7453/gahmj.2013.009 ↗
30. 10.1038/nmat244210.1038/nmat2442 ↗
31. 10.4161/cib.2793410.4161/cib.27934 ↗
32. 10.1016/j.ejcb.2015.06.01010.1016/j.ejcb.2015.06.010 ↗
33. 10.1038/s41598-017-07494-010.1038/s41598-017-07494-0 ↗
34. 10.1016/j.pharmthera.2013.12.00410.1016/j.pharmthera.2013.12.004 ↗
35. 10.1038/nature0487010.1038/nature04870 ↗
36. 10.1158/1078-0432.ccr-08-012510.1158/1078-0432.ccr-08-0125 ↗
37. 10.1038/nrc78010.1038/nrc780 ↗
38. 10.1016/j.ccr.2005.08.00810.1016/j.ccr.2005.08.008 ↗
39. 10.4161/cc.2.4.43310.4161/cc.2.4.433 ↗
40. 10.1042/bst2013015610.1042/bst20130156 ↗
41. 10.1186/1747-1028-7-2610.1186/1747-1028-7-26 ↗
42. 10.1242/jcs.00953010.1242/jcs.009530 ↗
43. 10.1038/sj.emboj.760189910.1038/sj.emboj.7601899 ↗
44. Liu J. L. · Int. J. Oncol. · 2011 · 39 · 915
45. 10.1016/j.dnarep.2004.03.02410.1016/j.dnarep.2004.03.024 ↗
46. 10.1016/j.mrgentox.2005.12.00410.1016/j.mrgentox.2005.12.004 ↗
47. 10.1038/ncb88410.1038/ncb884 ↗
48. 10.4161/cc.2.5.50910.4161/cc.2.5.509 ↗
49. 10.1038/cddiscovery.2016.1110.1038/cddiscovery.2016.11 ↗
50. 10.1016/j.molcel.2006.05.02310.1016/j.molcel.2006.05.023 ↗
51. 10.1073/pnas.100217510710.1073/pnas.1002175107 ↗
52. 10.1111/j.1742-4658.2010.07975.x10.1111/j.1742-4658.2010.07975.x ↗
53. 10.1038/nrm215310.1038/nrm2153 ↗
54. 10.1038/nrm149610.1038/nrm1496 ↗
55. 10.1186/1477-7827-7-14310.1186/1477-7827-7-143 ↗
56. 10.1124/mol.105.01540410.1124/mol.105.015404 ↗